Zevra reports Q4 net loss $9.0M ($0.26/sh); cash $102.9M; arimoclomol NDA resubmission on track for Q3 2023

ZEVRA THERAPEUTICS, INC.

Q4 net revenue $2.3M (vs $2.6M in Q4 2021); net loss ($9.0M) or ($0.26)/share vs ($2.7M)/($0.08).
FY 2022 net revenue $10.5M (down from $28.7M); net loss ($41.5M) or ($1.20)/share vs ($62.9M)/($2.11) in 2021.
Cash, cash equivalents and investments $102.9M as of Dec 31, 2022; cash runway extended into 2026.
Arimoclomol NDA resubmission for NPC anticipated as early as Q3 2023.
KP1077 Phase 2 trial for IH: interim data expected as early as Q3 2023, top-line by year-end 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ZEVRA THERAPEUTICS, INC. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $2.3 million, net income ($9.0) million, or ($0.26) per basic and diluted share, EPS ($0.26) per basic and diluted share.

Period: fourth quarter and fiscal year ended December 31, 2022
Revenue: $2.3 million
Net income: ($9.0) million, or ($0.26) per basic and diluted share
EPS: ($0.26) per basic and diluted share
Result: reported results

Exact text from the filing

Page 3 Overview of Fourth Quarter (Q4) and Full-Year (FY) 2022 Financial Results: Net revenue for Q4 2022 was $2.3 million, as compared to Q4 2021 net revenue of $2.6 million. Q4 2022 net revenue was primarily driven by ongoing reimbursements received from the French early access program for arimoclomol, AZSTARYS® royalty revenues and consulting fees.

View on SEC.gov

Browse all earnings releases →

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-005593

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.